INSYS Therapeutics, Inc. Sustainability Profile
INSYS Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2010, the company has made significant strides in developing innovative therapies, particularly in the areas of pain management and substance use disorders. INSYS is renowned for its unique delivery systems, including sublingual formulations that enhance the bioavailability of cannabinoids. Their flagship products, such as Syndros, have positioned the company as a leader in the treatment of chemotherapy-induced nausea and vomiting. With a commitment to advancing patient care, INSYS Therapeutics has achieved notable milestones, including successful FDA approvals and a growing portfolio of proprietary products. The company continues to focus on addressing unmet medical needs, solidifying its market position in the evolving landscape of therapeutics.
DitchCarbon Score
How does INSYS Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
INSYS Therapeutics, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
INSYS Therapeutics, Inc.'s reported carbon emissions
INSYS Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions data or reduction initiatives available, it is unclear how INSYS Therapeutics is addressing climate change or its carbon footprint. The lack of reported emissions and commitments places the company in a context where it may need to enhance its climate strategy to align with industry best practices and stakeholder expectations.
How Carbon Intensive is INSYS Therapeutics, Inc.'s Industry?
How Carbon Intensive is INSYS Therapeutics, Inc.'s Location?
INSYS Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
INSYS Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
